**CRYPTOGENIC STROKE PATHWAY**

**PATIENT DIAGNOSED WITH CRYPTOGENIC STROKE/TIA**

- Could detection of suspected AF impact patient management?
  - **YES**
    - Refer to cardiology to insert Reveal LINQ™ ICM
  - **NO**
    - Not a candidate

**Inpatient**
- Inpatient/outpatient insertion
  - If unable to insert prior to discharge, potential external monitor bridge and schedule Reveal LINQ ICM

**Outpatient**
- Insert expeditiously
  - Bridge with external monitor
    - AF not detected
    - AF detected
      - Insert Reveal LINQ ICM

**Enroll in CareLink™ Network & perform remote monitoring**
- Schedule clinical follow-up with treating physician and ensure long-term adherence to monitoring

Pathway based on the consensus of the Cryptogenic Stroke Pathway steering committee. February 2016.

Medtronic Disclosure Statement: This pathway is provided for educational purposes and should not be considered the exclusive source for this type of information. It is the responsibility of the practitioner to exercise independent clinical judgment.

Refer to the brief statement for indications, warnings/precautions, and complications for the Reveal LINQ ICM.
WHEN TO CONSIDER LOOKING FOR AF IN CRYPTOGENIC STROKE PATIENTS

Appropriate

- Stroke detected by CT or MRI that is not lacunar$^1$
- Absence of extracranial or intracranial atherosclerosis causing $\geq 50\%$ luminal stenosis in arteries supplying the area of ischaemia$^1$
- No major-risk cardioembolic source of embolism$^1$
- No other specific cause of stroke identified (e.g., arteritis, dissection, migraine/vasospasm, drug misuse)$^1$
- First event — Stroke or High-Risk TIA$^*$
- CHADS$_2$ score $\geq 2$ (Minimal risk factors)

Not Appropriate

- Indication for chronic anticoagulation or already on anticoagulation
- Patients with a relative contraindication for long-term anticoagulation and not appropriate for LAA closure device

$^*$ ABCD2 Score $>5$

Pathway based on the consensus of the Cryptogenic Stroke Pathway steering committee. February 2016.

Reference


Brief Statement

Indications: Reveal LINQ™ LNQ11 Insertable Cardiac Monitor and Patient Assistant

The Reveal LINQ Insertable Cardiac Monitor is an implantable patient-activated and automatically-activated monitoring system that records subcutaneous ECG and is indicated in the following cases:

- Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
- Patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain, that may suggest a cardiac arrhythmia

This device has not specifically been tested for pediatric use.

Patient Assistant: The Patient Assistant is intended for unsupervised patient use away from a hospital or clinic. The Patient Assistant activates the data management feature in the Reveal™ Insertable Cardiac Monitor to initiate recording of cardiac event data in the implanted device memory.

Contraindications: There are no known contraindications for the implant of the Reveal LINQ Insertable Cardiac Monitor. However, the patient’s particular medical condition may dictate whether or not a subcutaneous, chronically implanted device can be tolerated.

Warnings/Precautions: Reveal LINQ LNQ11 Insertable Cardiac Monitor

Patients with the Reveal LINQ Insertable Cardiac Monitor should avoid sources of diathermy, high sources of radiation, electrosurgical cautery, external defibrillation, lithotripsy, therapeutic ultrasound, and radiofrequency ablation to avoid electrical reset of the device, and/or inappropriate sensing as described in the Medical procedure and EMI precautions manual. MRI scans should be performed only in a specified MR environment under specified conditions as described in the Reveal LINQ MRI Technical Manual.

Patient Assistant: Operation of the Patient Assistant near sources of electromagnetic interference, such as cellular phones, computer monitors, etc., may adversely affect the performance of this device.

Potential Complications: Potential complications include, but are not limited to, device rejection phenomena (including local tissue reaction), device migration, infection, and erosion through the skin.

See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1 (800) 328-2518 and/or consult Medtronic’s website at www.medtronic.com.

Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.